| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | MRC; MOX1; MOX2; OX-2 |
| Entrez GeneID | 4345 |
| clone | 3G1C9 |
| WB Predicted band size | 31.3kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD200 (AA:Extra(31-232)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD200抗体的3篇文献示例(信息经过简化处理)：
1. **《CD200 blockade modulates tumor microenvironment and enhances chemo-response in epithelial ovarian cancer》**
- 作者：Wei et al. (2020)
- 摘要：研究证明抗CD200抗体通过抑制CD200-CD200R免疫抑制通路，重塑肿瘤微环境，增强T细胞抗肿瘤活性，并提高卵巢癌细胞对化疗的敏感性。
2. **《CD200 expression in dendritic cells is required for the induction of regulatory T cells》**
- 作者：Gorczynski et al. (2018)
- 摘要：揭示树突状细胞表面CD200通过调控Treg细胞分化维持免疫耐受，使用中和抗体阻断CD200可减少Treg生成，增强抗病毒免疫应答。
3. **《Targeting CD200-CD200R immune checkpoint axis in experimental autoimmune encephalomyelitis》**
- 作者：Coles et al. (2019)
- 摘要：在多发性硬化症小鼠模型中，抗CD200抗体通过解除髓鞘抗原特异性T细胞抑制，减轻中枢神经系统炎症损伤，为神经免疫疾病提供治疗策略。
注：以上文献信息为示例性质，实际文献需通过学术数据库查询。建议通过PubMed或Web of Science以"CD200 antibody"为关键词检索最新研究。
The CD200 antibody targets the CD200 glycoprotein, a cell surface molecule belonging to the immunoglobulin superfamily. CD200. also known as OX-2. functions as an immunoregulatory protein by interacting with its receptor, CD200R, primarily expressed on myeloid cells such as macrophages, dendritic cells, and microglia. This interaction delivers inhibitory signals that suppress immune activation, promoting immune tolerance and reducing inflammatory responses. Dysregulation of the CD200-CD200R axis is implicated in autoimmune diseases, cancer immune evasion, and chronic infections, making it a therapeutic target.
In cancer, tumor cells often overexpress CD200 to dampen antitumor immunity by engaging CD200R on immune cells, thereby inhibiting their effector functions. CD200-blocking antibodies aim to disrupt this interaction, restoring immune cell activity against tumors. Preclinical studies show that anti-CD200 antibodies enhance T-cell responses and reduce immunosuppressive myeloid cell activity. Clinical trials, such as those involving samalizumab, have explored their potential in hematologic malignancies like chronic lymphocytic leukemia and multiple myeloma, though outcomes have been mixed, highlighting the need for further optimization.
In autoimmune and inflammatory disorders, CD200 agonists or antagonists are being investigated to modulate immune hyperactivity. For example, enhancing CD200 signaling could suppress excessive inflammation in diseases like rheumatoid arthritis. However, challenges remain, including understanding tissue-specific CD200/CD200R dynamics and minimizing off-target effects. Overall, CD200 antibodies represent a promising but complex therapeutic avenue, requiring deeper mechanistic insights to balance efficacy and safety.
×
